Definium Therapeutics, Inc. (DFTX) Financial Statements
Free cash flow over the same period: -$168.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DFTXDefinium Therapeutics, Inc.Follow DFTX — free
—
Price chart with a free account
- Market cap
- 4.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 0.03 | 0.04 | 0.05 | 0.07 | 0.12 | 0.15 | |
| Operating income | -0.09 | -0.07 | -0.09 | -0.10 | -0.17 | -0.23 | |
| Pre-tax income | -0.09 | -0.06 | -0.10 | -0.11 | -0.18 | -0.35 | |
| Income tax | -0.00 | — | — | — | 0.00 | — | |
| Net income | -0.09 | -0.06 | -0.10 | -0.11 | -0.18 | -0.35 | |
| Diluted EPS ($) | -0.23 | -1.84 | -2.44 | -1.54 | -2.06 | -3.20 | |
| Diluted shares (bn) | — | 0.031 | 0.039 | 0.070 | 0.089 | — |
USD billions · SEC XBRL
Definium Therapeutics, Inc. — questions
- What is Definium Therapeutics, Inc.'s net income?
- -$353.8M over the twelve months to 2026-06-30.
- What is Definium Therapeutics, Inc.'s free cash flow?
- -$168.0M over the twelve months to 2026-06-30.
- What are Definium Therapeutics, Inc.'s diluted earnings per share?
- $-3.20 over the twelve months to 2026-06-30.
Every figure on this page comes from Definium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.